BOSTON and LOUISVILLE, Ky., April 23, 2024 /PRNewswire/ -- Cohere Health, a recognized leader in clinical intelligence and prior authorization automation, announced that Humana Inc. (NYSE: HUM) will expand its use of Cohere's prior authorization platform for diagnostic imaging and sleep services.
"Expanding our partnership with Cohere further supports our commitment to improving prior authorization for our members and providers," said Lisa Stephens, Senior Vice President of Clinical Operations at Humana. "Diagnostic imaging is often the start of a patient's journey, and we are confident our collaboration will further elevate our members' overall healthcare journey and streamline administrative tasks for our providers."
In January 2021, Cohere and Humana began a pilot program in 12 states to improve the prior authorization process for musculoskeletal (MSK) services. The program successfully reduced prior authorization approval turnaround times, increased provider satisfaction, and enhanced care delivery for MSK services, which resulted in an expansion across all 50 states in 2022. In January 2023, Cohere's solutions were deployed nationwide to include cardiovascular and surgical services.
"We're pleased Humana will be utilizing our diagnostic imaging and sleep solutions, further strengthening our strategic and ongoing partnership," said Siva Namasivayam, Chief Executive Officer of Cohere Health. "Our solutions are rooted in the latest evidenced-based guidelines from leading medical societies and use advanced technology to align patient services within care pathways through upstream moments of influence, ultimately enabling faster diagnoses."
Cohere's prior authorization platform helps providers and patients get to 'yes' more quickly. Cohere's unique blend of real-time analytics and deep, evidence-based clinical intelligence reduces prior authorization denial rates and leads to faster patient access to care.
Cohere processes 5.5 million prior authorizations annually, positively impacting more than 15 million health plan members and 420,000 healthcare providers nationwide.
Cohere Health is a clinical intelligence company that provides prior authorization as a springboard to better quality outcomes by aligning physicians and health plans on evidence-based care paths for the patient's entire care journey. Cohere's prior authorization solutions reduce administrative expenses while improving patient outcomes. The company is a Top 5 LinkedIn™ Startup, winner of the TripleTree iAward, consecutive KLAS Research's Points of Light recipient, and has been named to Fierce Healthcare's Fierce 15 and CB Insights' Digital Health 150 lists. Cohere's investors include Flare Capital Partners, Define Ventures, Deerfield, Polaris Partners, and Longitude Capital.
About Humana
Humana Inc. is committed to putting health first – for our teammates, customers, and company. Through our Humana insurance services and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com.
CONTACT:
Kat Long
anthonyBarnum Public Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Justin Burkhardt
Cohere Health
This email address is being protected from spambots. You need JavaScript enabled to view it.
Jahna Lindsay-Jones
Humana Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$293.97 |
Daily Change: | 16.19 5.83 |
Daily Volume: | 2,221,854 |
Market Cap: | US$35.400B |
November 12, 2024 October 30, 2024 October 24, 2024 October 23, 2024 August 19, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB